Theravance Biopharma TBPH Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $114.54M+296% | $105.9M+288% | $29.34M+159% | $13.03M+129% | -$58.33M-30.3% | ||
| $1.59M-5.7% | $1.63M-4.9% | $1.65M-1.8% | $1.67M-0.6% | $1.69M-6.5% | ||
| $18.1M-14.0% | $18.48M-13.6% | $19.82M-7.3% | $20.21M-10.9% | $21.04M-10.8% | ||
| —— | —— | —— | $245.02M+2,892% | $32.53M+294% | ||
| -$83.91M— | -$105.87M— | -$90.19M— | -$7.34M— | —— | ||
| -$7.97M-388% | -$3.25M-30.1% | -$2.12M+93.5% | -$2.09M+96.7% | -$1.64M+98.9% | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Theravance Biopharma generate?
- Theravance Biopharma (TBPH) generated $323.5M in operating cash flow over the trailing twelve months.
- Where does Theravance Biopharma's cash flow data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
